Literature DB >> 16927344

Bis-tetrahydrofuran: a privileged ligand for darunavir and a new generation of hiv protease inhibitors that combat drug resistance.

Arun K Ghosh1, Perali Ramu Sridhar, Nagaswamy Kumaragurubaran, Yasuhiro Koh, Irene T Weber, Hiroaki Mitsuya.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16927344     DOI： 10.1002/cmdc.200600103

Source DB:  PubMed          Journal:  ChemMedChem        ISSN： 1860-7179            Impact factor:   3.466


× No keyword cloud information.
  43 in total

1.  Novel HIV-1 Protease Inhibitors with Morpholine as the P2 Ligand to Enhance Activity against DRV-Resistant Variants.

Authors:  Mei Zhu; Yue Dou; Ling Ma; Biao Dong; Fan Zhang; Guoning Zhang; Juxian Wang; Jinming Zhou; Shan Cen; Yucheng Wang
Journal:  ACS Med Chem Lett       Date:  2020-03-31       Impact factor: 4.345

2.  Potent new antiviral compound shows similar inhibition and structural interactions with drug resistant mutants and wild type HIV-1 protease.

Authors:  Yuan-Fang Wang; Yunfeng Tie; Peter I Boross; Jozsef Tozser; Arun K Ghosh; Robert W Harrison; Irene T Weber
Journal:  J Med Chem       Date:  2007-08-16       Impact factor: 7.446

3.  Design of HIV-1 protease inhibitors with C3-substituted hexahydrocyclopentafuranyl urethanes as P2-ligands: synthesis, biological evaluation, and protein-ligand X-ray crystal structure.

Authors:  Arun K Ghosh; Bruno D Chapsal; Garth L Parham; Melinda Steffey; Johnson Agniswamy; Yuan-Fang Wang; Masayuki Amano; Irene T Weber; Hiroaki Mitsuya
Journal:  J Med Chem       Date:  2011-07-29       Impact factor: 7.446

Review 4.  Tetrahydrofuran, tetrahydropyran, triazoles and related heterocyclic derivatives as HIV protease inhibitors.

Authors:  Arun K Ghosh; David D Anderson
Journal:  Future Med Chem       Date:  2011-07       Impact factor: 3.808

5.  Enantioselective Synthesis of Dioxatriquinane Structural Motifs for HIV-1 Protease Inhibitors Using a Cascade Radical Cyclization.

Authors:  Arun K Ghosh; Chun-Xiao Xu; Heather L Osswald
Journal:  Tetrahedron Lett       Date:  2015-06-03       Impact factor: 2.415

6.  Design of novel HIV-1 protease inhibitors incorporating isophthalamide-derived P2-P3 ligands: Synthesis, biological evaluation and X-ray structural studies of inhibitor-HIV-1 protease complex.

Authors:  Arun K Ghosh; Margherita Brindisi; Prasanth R Nyalapatla; Jun Takayama; Jean-Rene Ella-Menye; Sofiya Yashchuk; Johnson Agniswamy; Yuan-Fang Wang; Manabu Aoki; Masayuki Amano; Irene T Weber; Hiroaki Mitsuya
Journal:  Bioorg Med Chem       Date:  2017-04-09       Impact factor: 3.641

7.  Design and Synthesis of Potent HIV-1 Protease Inhibitors Containing Bicyclic Oxazolidinone Scaffold as the P2 Ligands: Structure-Activity Studies and Biological and X-ray Structural Studies.

Authors:  Arun K Ghosh; Jacqueline N Williams; Rachel Y Ho; Hannah M Simpson; Shin-Ichiro Hattori; Hironori Hayashi; Johnson Agniswamy; Yuan-Fang Wang; Irene T Weber; Hiroaki Mitsuya
Journal:  J Med Chem       Date:  2018-10-24       Impact factor: 7.446

8.  A poke in the eye: inhibiting HIV-1 protease through its flap-recognition pocket.

Authors:  Kelly L Damm; Peter M U Ung; Jerome J Quintero; Jason E Gestwicki; Heather A Carlson
Journal:  Biopolymers       Date:  2008-08       Impact factor: 2.505

9.  A copper(I)-catalyzed 1,2,3-triazole azide-alkyne click compound is a potent inhibitor of a multidrug-resistant HIV-1 protease variant.

Authors:  Michael J Giffin; Holly Heaslet; Ashraf Brik; Ying-Chuan Lin; Gabrielle Cauvi; Chi-Huey Wong; Duncan E McRee; John H Elder; C David Stout; Bruce E Torbett
Journal:  J Med Chem       Date:  2008-09-30       Impact factor: 7.446

10.  Design, Synthesis, Biological Evaluation, and X-ray Studies of HIV-1 Protease Inhibitors with Modified P2' Ligands of Darunavir.

Authors:  Arun K Ghosh; W Sean Fyvie; Margherita Brindisi; Melinda Steffey; Johnson Agniswamy; Yuan-Fang Wang; Manabu Aoki; Masayuki Amano; Irene T Weber; Hiroaki Mitsuya
Journal:  ChemMedChem       Date:  2017-11-24       Impact factor: 3.466
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.